Mode
Text Size
Log in / Sign up

Baseline vitamin D deficiency occurred in 73.08% of TAO patients receiving IVGC therapy with calcium supplementation.

Baseline vitamin D deficiency occurred in 73.08% of TAO patients receiving IVGC therapy with calcium…
Photo by Ben Maffin / Unsplash
Key Takeaway
Note that baseline 25(OH)D deficiency was present in 73.08% of TAO patients receiving IVGC therapy.

This retrospective cohort study included 52 patients with thyroid-associated ophthalmopathy who completed intravenous glucocorticoid (IVGC) therapy with standardized vitamin D and calcium supplementation at the First Affiliated Hospital of Xi'an Jiaotong University. The study assessed treatment response to IVGC alongside baseline biomarkers including triglycerides, thyroxine, duration of ophthalmopathy, beta-CTX, N-MID OC, and 25(OH)D levels.

Analysis revealed that baseline triglycerides and thyroxine levels were significantly higher in non-responders compared to responders. Additionally, the duration of ophthalmopathy was longer in non-responders. Conversely, baseline beta-CTX and N-MID OC levels were higher in responders. Baseline 25(OH)D deficiency was present in 73.08% of the patients.

Safety and tolerability data were not reported, as were discontinuations and serious adverse events. The study notes that the relationship between vitamin D and IVGC efficacy remains undefined. Because this is an observational study, causal inferences cannot be made regarding the impact of vitamin D supplementation or baseline biomarkers on treatment outcomes.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundIntravenous glucocorticoids (IVGC) represent first-line therapy for active moderate-to-severe thyroid-associated ophthalmopathy (TAO). The relationship between vitamin D (VitD) and IVGC efficacy in TAO remains undefined.MethodsThis retrospective study grouped TAO patients completing IVGC therapy with standardized VitD/calcium supplementation at First Affiliated Hospital of Xi’an Jiaotong University (2015–2019). Serum 25-hydroxyvitamin D (25(OH)D) and bone markers were measured pre/post-treatment. Multivariate regression and ROC analysis identified predictors.ResultsIn total, 52 TAO patients were enrolled, including 33 responders and 19 non-responders. Non-responders had significantly higher baseline triglycerides, thyroxine and longer duration of ophthalmopathy. Responders exhibited higher baseline β-CTX and N-MID OC. Notably, 73.08% of patients had baseline 25(OH)D deficiency (
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.